Affini-T Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the field of gene editing. The company is focused on developing innovative therapies for cancer treatment, with a particular emphasis on targeting the KRAS G12D gene mutation, a common mutation in many types of cancer.

The company's primary clients are healthcare providers and patients suffering from cancer. Affini-T Therapeutics operates in the highly competitive and rapidly evolving biotechnology market, which is driven by advancements in scientific research and technology.

The business model of Affini-T Therapeutics is based on research and development (R&D). The company invests heavily in R&D to develop new gene editing therapies. Once these therapies are developed and approved for use, the company generates revenue by selling these therapies to healthcare providers.

The company recently appointed Kathy Bergsteinsson, a veteran in healthcare capital markets, as its Chief Financial Officer, and Thaminda Ramanayake, an industry veteran, as its Chief Business Officer. These appointments suggest that the company is gearing up for significant business growth and expansion.

Affini-T Therapeutics also actively participates in scientific conferences, such as the Society for Immunotherapy of Cancer (SITC) Annual Meeting, to present its preclinical gene editing data. This not only helps the company to stay updated with the latest developments in the field but also provides opportunities to network with other industry players and potential clients.

Keywords: Biotechnology, Healthcare, Gene Editing, Cancer Treatment, KRAS G12D, Research and Development, Healthcare Providers, Scientific Conferences, Business Growth, Industry Veterans.